Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data

Polatuzumab vedotin plus bendamustine and rituximab (pola + BR) received regulatory approvals for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) based on primary results from the randomized arms of the GO29365 study. After the randomized phase, 106 additional patients received pola +...

Descripción completa

Detalles Bibliográficos
Autores principales: Sehn, Laurie H., Hertzberg, Mark, Opat, Stephen, Herrera, Alex F., Assouline, Sarit, Flowers, Christopher R., Kim, Tae Min, McMillan, Andrew, Ozcan, Muhit, Safar, Violaine, Salles, Gilles, Ku, Grace, Hirata, Jamie, Chang, Yi Meng, Musick, Lisa, Matasar, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791582/
https://www.ncbi.nlm.nih.gov/pubmed/34749395
http://dx.doi.org/10.1182/bloodadvances.2021005794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791582/
https://www.ncbi.nlm.nih.gov/pubmed/34749395
http://dx.doi.org/10.1182/bloodadvances.2021005794

Ejemplares similares